Prudential Financial’s C4 Therapeutics CCCC Stock Holding History

Prudential Financial’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$41.9K	Buy	15,950 +900	+6%	+$2.12K	﹤0.01%	2337
2025 Q4	$28.7K	Buy	15,050 +750	+5%	+$1.78K	﹤0.01%	2181
2025 Q3	$31.7K	Buy	+14,300	New	+$34.3K	﹤0.01%	2380
2024 Q4	–	Sell	-12,025	Closed	-$68.5K	–	2342
2024 Q3	$68.5K	Hold	12,025	–	–	﹤0.01%	2613
2024 Q2	$55.6K	Buy	+12,025	New	+$71.7K	﹤0.01%	2603
2021 Q4	–	Sell	-23,270	Closed	-$1.04M	–	2643
2021 Q3	$1.04M	Buy	23,270 +700	+3%	+$30K	﹤0.01%	1783
2021 Q2	$854K	Sell	22,570 -1,170	-5%	-$41.9K	﹤0.01%	1907
2021 Q1	$879K	Buy	+23,740	New	+$944K	﹤0.01%	1892

Other funds holding CCCC

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prudential Financial's CCCC Position: Q1 2026 in Review

Prudential Financial increased its C4 Therapeutics (CCCC) stake by 6% in Q1 2026, buying an estimated $2.12K and bringing the position to 15,950 shares worth $41.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2337.

Prudential Financial first reported a position in CCCC in Q1 2021 and has held it in 8 quarters since. The position peaked at $1.04M in Q3 2021. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

Prudential Financial held 15,950 shares of C4 Therapeutics worth $41.9K as of Q1 2026.
Prudential Financial bought 900 C4 Therapeutics shares in Q1 2026, an estimated $2.12K.
C4 Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q1 2026, its #2337 holding.
Prudential Financial first reported a position in C4 Therapeutics in Q1 2021 and has held it in 8 quarters since.
Prudential Financial's C4 Therapeutics position peaked at $1.04M in Q3 2021.
123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Prudential Financial's 13F filing for Q1 2026, filed 13 May 2026.